Latest Commercialisation News

BlinkLab is advancing its FDA 510(k) clinical trials for autism and ADHD diagnostics, completing its U.S. autism pilot phase and expanding European ADHD recruitment. A recent $7.66 million capital raise supports these efforts as the company targets regulatory approvals in 2026.

Echo IQ has secured a strategic collaboration with the Mayo Clinic Platform and raised $17.3 million, advancing its AI-driven cardiology tools towards FDA clearance and US commercial scale.

IPB Petroleum has secured a crucial two-year extension on its WA-424-P permit in the Browse Basin, allowing more time to progress the Gwydion oil discovery and explore the Idris prospect. The company is actively pursuing partnerships and funding to unlock value from these assets.

Gold Hydrogen Limited has locked in a $14.5 million strategic investment from major Japanese corporations to fund expanded drilling and appraisal at its Ramsay Project in South Australia. This capital injection aims to advance the company’s pioneering work in Natural Hydrogen and Helium exploration.

Adisyn Ltd has made significant strides in developing low-temperature graphene semiconductor interconnects, commissioning a new Atomic Layer Deposition system and securing a major managed IT services contract, while maintaining a strong cash position.

Hiremii Limited reported a 4.4% revenue increase in Q4 FY25 alongside positive operating cash flow, while accelerating commercialisation of its proprietary AI recruitment platform and expanding through a key acquisition.

Patrys Limited has launched a fully underwritten entitlement offer to raise approximately $1.77 million, aiming to accelerate development and commercial activities around its deoxymabs program.

Lincoln Minerals Limited has unveiled a comprehensive update on its critical minerals projects in South Australia’s Gawler Craton, highlighting imminent drilling approvals at the Minbrie copper-base metals project and strong progress across graphite, uranium, and high purity iron assets.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart technology, reporting promising clinical results in Crohn’s disease and GVHD, alongside a $3.5 million capital raise to fuel next-stage development.

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

Sunshine Metals has launched an advanced scoping study targeting 95,000 ounces of gold and 652,000 ounces of silver at its Liontown project in North Queensland. The study aims to optimise extraction from multiple high-grade resource domains, with metallurgical test results expected in August 2025.

Firebrick Pharma has published positive Phase 3 clinical trial results for its Nasodine nasal spray, showing efficacy against the common cold, while reporting encouraging sales growth in Singapore and the US. However, a recent capital raise fell well short of targets, casting uncertainty over its expansion plans.